Download MendeleyThe monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.
Copin, R., Baum, A., Wloga, E., Pascal, K.E., Giordano, S., Fulton, B.O., Zhou, A., Negron, N., Lanza, K., Chan, N., Coppola, A., Chiu, J., Ni, M., Wei, Y., Atwal, G.S., Hernandez, A.R., Saotome, K., Zhou, Y., Franklin, M.C., Hooper, A.T., McCarthy, S., Hamon, S., Hamilton, J.D., Staples, H.M., Alfson, K., Carrion Jr., R., Ali, S., Norton, T., Somersan-Karakaya, S., Sivapalasingam, S., Herman, G.A., Weinreich, D.M., Lipsich, L., Stahl, N., Murphy, A.J., Yancopoulos, G.D., Kyratsous, C.A.(2021) Cell 184: 3949
- PubMed: 34161776
- DOI: https://doi.org/10.1016/j.cell.2021.06.002
- Primary Citation of Related Structures:
7M42 - PubMed Abstract:
Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option against COVID-19. Because rapidly emerging virus mutants are becoming the next major concern in the fight against the global pandemic, it is imperative that these therapeutic treatments provide coverage against circulating variants and do not contribute to development of treatment-induced emergent resistance. To this end, we investigated the sequence diversity of the spike protein and monitored emergence of virus variants in SARS-COV-2 isolates found in COVID-19 patients treated with the two-antibody combination REGEN-COV, as well as in preclinical in vitro studies using single, dual, or triple antibody combinations, and in hamster in vivo studies using REGEN-COV or single monoclonal antibody treatments. Our study demonstrates that the combination of non-competing antibodies in REGEN-COV provides protection against all current SARS-CoV-2 variants of concern/interest and also protects against emergence of new variants and their potential seeding into the population in a clinical setting.
Organizational Affiliation:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.
